
## Erich V De Paula

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7918127/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene Transfer to Skeletal Muscle in an Individual with Severe Hemophilia B. Molecular Therapy, 2006, 14, 452-455.	3.7	196
2	HRT Atlas v1.0 database: redefining human and mouse housekeeping genes and candidate reference transcripts by mining massive RNA-seq datasets. Nucleic Acids Research, 2021, 49, D947-D955.	6.5	145
3	Platelet-rich plasma (PRP) and adipose-derived mesenchymal stem cells: stimulatory effects on proliferation and migration of fibroblasts and keratinocytes in vitro. Archives of Dermatological Research, 2016, 308, 511-520.	1.1	79
4	Recombinant factorÂVIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. Journal of Thrombosis and Haemostasis, 2014, 12, 1244-1253.	1.9	61
5	Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective. BMC Medicine, 2015, 13, 105.	2.3	56
6	Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leukemia Research, 2004, 28, 587-594.	0.4	54
7	Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. Journal of Thrombosis and Haemostasis, 2015, 13, 1989-1998.	1.9	54
8	Folate, Vitamin B12 and Homocysteine status in the post-folic acid fortification era in different subgroups of the Brazilian population attended to at a public health care center. Nutrition Journal, 2015, 14, 19.	1.5	52
9	Role of innate immunity-triggered pathways in the pathogenesis of Sickle Cell Disease: a meta-analysis of gene expression studies. Scientific Reports, 2015, 5, 17822.	1.6	48
10	Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets, 2008, 19, 489-495.	1.1	46
11	Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance. Haematologica, 2020, 105, 2380-2390.	1.7	43
12	Association of the immature platelet fraction with sepsis diagnosis and severity. Scientific Reports, 2015, 5, 8019.	1.6	42
13	Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. Journal of Thrombosis and Haemostasis, 2012, 10, 1967-1970.	1.9	39
14	Thirdâ€ŧrimester erythrocytapheresis in pregnant patients with sickle cell disease. International Journal of Gynecology and Obstetrics, 2007, 96, 8-11.	1.0	36
15	Causes of incidental neutropenia in adulthood. Annals of Hematology, 2006, 85, 705-709.	0.8	35
16	Evaluation of the immature platelet fraction contribute to the differential diagnosis of hereditary, immune and other acquired thrombocytopenias. Scientific Reports, 2017, 7, 3355.	1.6	35
17	Recombinant factorÂVIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. Journal of Thrombosis and Haemostasis, 2012, 10, 81-89.	1.9	33
18	Reduced thrombin formation and excessive fibrinolysis are associated with bleeding complications in patients with dengue fever: a case–control study comparing dengue fever patients with and without bleeding manifestations. BMC Infectious Diseases, 2013, 13, 350.	1.3	30

#	Article	IF	CITATIONS
19	Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study. Journal of Translational Medicine, 2011, 9, 23.	1.8	29
20	Elevated hypercoagulability markers in hemoglobin SC disease. Haematologica, 2015, 100, 466-471.	1.7	29
21	Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. Thrombosis Research, 2015, 136, 1174-1178.	0.8	28
22	Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy. Hematology, Transfusion and Cell Therapy, 2020, 42, 300-308.	0.1	28
23	Bartonella henselaeInfects Human Erythrocytes. Ultrastructural Pathology, 2007, 31, 369-372.	0.4	27
24	Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123Âcountries. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12520.	1.0	27
25	Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia. BMC Infectious Diseases, 2010, 10, 143.	1.3	26
26	Increased ADAMTS13 activity in patients with venous thromboembolism. Thrombosis Research, 2012, 130, 889-893.	0.8	26
27	Circulating Progenitor and Mature Endothelial Cells in Deep Vein Thrombosis. International Journal of Medical Sciences, 2013, 10, 1746-1754.	1.1	26
28	Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated WithÂImatinib. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 728-733.	0.2	26
29	A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Critical Care, 2013, 17, R169.	2.5	24
30	Increased adhesive properties of neutrophils and inflammatory markers in venous thromboembolism patients with residual vein occlusion and high D-dimer levels. Thrombosis Research, 2014, 133, 736-742.	0.8	24
31	Long-term increased factor VIII levels are associated to interleukin-6 levels but not to post-thrombotic syndrome in patients with deep venous thrombosis. Thrombosis Research, 2015, 135, 497-501.	0.8	24
32	Long-term hydroxyurea therapy in beta-thalassaemia patients. European Journal of Haematology, 2003, 70, 151-155.	1.1	23
33	Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. Platelets, 2009, 20, 367-375.	1.1	23
34	Prolonged APTT of unknown etiology: A systematic evaluation of causes and laboratory resource use in an outpatient hemostasis academic unit. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 749-757.	1.0	23
35	Safety and efficacy of cryoprecipitateâ€poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: A single center retrospective evaluation. Journal of Clinical Apheresis, 2014, 29, 311-315.	0.7	22
36	Novel insights into the development of atherosclerosis in hemophiliaÂA mouse models. Journal of Thrombosis and Haemostasis, 2011, 9, 1556-1561.	1.9	21

#	Article	IF	CITATIONS
37	Circulating levels of the angiogenesis mediators endoglin, HB-EGF, BMP-9 and FGF-2 in patients with severe sepsis and septic shock. Journal of Critical Care, 2017, 42, 162-167.	1.0	20
38	Prophylactic anticoagulation for patients in hospital with covid-19. BMJ, The, 2021, 372, n487.	3.0	20
39	Polymorphisms and Mutations in <i>vWF</i> and <i>ADAMTS13</i> Genes and Their Correlation With Plasma Levels of FVIII and vWF in Patients With Deep Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 514-518.	0.7	19
40	Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban. Vascular Pharmacology, 2020, 124, 106608.	1.0	19
41	Tissue factor-dependent coagulation activation by heme: A thromboelastometry study. PLoS ONE, 2017, 12, e0176505.	1.1	19
42	Guideline on immune thrombocytopenia in adults: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Project guidelines: Associação Médica Brasileira – 2018. Hematology, Transfusion and Cell Therapy, 2018, 40, 50-74.	0.1	18
43	Increased inflammation and endothelial markers in patients with late severe post-thrombotic syndrome. PLoS ONE, 2020, 15, e0227150.	1.1	18
44	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2022, 20, 409-421.	1.9	17
45	Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19. Blood Advances, 2022, 6, 3367-3377.	2.5	17
46	Transfusion-transmitted infections among multi-transfused patients in Brazil. Journal of Clinical Virology, 2005, 34, S27-S32.	1.6	16
47	A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection. Transfusion, 2010, 50, 208-212.	0.8	16
48	Impairment of thrombin generation in the early phases of the host response of sepsis. Journal of Critical Care, 2014, 29, 31-36.	1.0	16
49	Immunological Hallmarks of Inflammatory Status in Vaso-Occlusive Crisis of Sickle Cell Anemia Patients. Frontiers in Immunology, 2021, 12, 559925.	2.2	15
50	Total parasite biomass but not peripheral parasitaemia is associated with endothelial and haematological perturbations in Plasmodium vivax patients. ELife, 2021, 10, .	2.8	15
51	VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thrombosis Research, 2010, 126, e206-e210.	0.8	14
52	Heat treatment of samples improve the performance of the Nijmegen–Bethesda assay in hemophilia A patients undergoing immune tolerance induction. Thrombosis Research, 2015, 136, 1280-1284.	0.8	14
53	Simultaneous bleeding and thrombosis in superwarfarin poisoning. Thrombosis Research, 2009, 123, 637-639.	0.8	13
54	Severe Post-thrombotic Syndrome is Associated With Higher Levels of Factor VIII. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 570-573.	0.7	13

#	Article	IF	CITATIONS
55	Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 162-166.	0.2	13
56	Platelet disturbances correlate with endothelial cell activation in uncomplicated Plasmodium vivax malaria. PLoS Neglected Tropical Diseases, 2020, 14, e0007656.	1.3	13
57	Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome. Thrombosis Research, 2022, 214, 132-137.	0.8	13
58	Dual gene transfer of fibroblast growth factor-2 andÂplatelet derived growth factor-BB using plasmidÂdeoxyribonucleic acid promotes effective angiogenesis and arteriogenesis in a rodent model ofÂhindlimb ischemia. Translational Research, 2009, 153, 232-239.	2.2	12
59	Prevalence of Factor IX-R338L (Factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels. Thrombosis Research, 2010, 126, e165.	0.8	11
60	Haemostatic management of extreme challenges to haemostasis in acquired von Willebrand syndrome. Haemophilia, 2012, 18, e188-91.	1.0	11
61	Laboratory evaluation of patients with undiagnosed bleeding disorders. Blood Coagulation and Fibrinolysis, 2016, 27, 500-505.	0.5	11
62	The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome. American Journal of Hematology, 2017, 92, 1163-1169.	2.0	11
63	Endothelial Barrier Integrity Is Disrupted In Vitro by Heme and by Serum From Sickle Cell Disease Patients. Frontiers in Immunology, 2020, 11, 535147.	2.2	11
64	Polymorphisms of interleukin-1 gene complex, IL6 and tumour necrosis factor genes in chronic idiopathic neutropenia of adults. Annals of Hematology, 2005, 84, 709-714.	0.8	10
65	Diagnosis of Scott syndrome in patient with bleeding disorder of unknown cause. Blood Coagulation and Fibrinolysis, 2012, 23, 75-77.	0.5	10
66	Circulating levels of tissue factor and the risk of thrombosis associated with antiphospholipid syndrome. Thrombosis Research, 2018, 171, 114-120.	0.8	10
67	Neutrophil extracellular trap regulators in sickle cell disease: Modulation of gene expression of PADI4, neutrophil elastase, and myeloperoxidase during vasoâ€occlusive crisis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 204-210.	1.0	10
68	Evaluation of Thrombin Generation in the Early Stages of Sepsis in Patients with Hematological Malignancies and Febrile Neutropenia,. Blood, 2011, 118, 3347-3347.	0.6	9
69	Long-term prospective study of recurrent venous thromboembolism in a Hispanic population. Blood Coagulation and Fibrinolysis, 2010, 21, 660-665.	0.5	8
70	Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial ( <scp>EDIâ€PIO</scp> ) in chronic myeloid leukemia with deep molecular response. American Journal of Hematology, 2020, 95, E321-E323.	2.0	8
71	Sickle Cell Anemia Patients Display an Intricate Cellular and Serum Biomarker Network Highlighted by TCD4+CD69+ Lymphocytes, IL-17/MIP-1 <i>β</i> , IL-12/VEGF, and IL-10/IP-10 Axis. Journal of Immunology Research, 2020, 2020, 1-22.	0.9	8
72	A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: Efficacy, safety and factors associated with treatment response. Journal of Thrombosis and Haemostasis, 2021, 19, 2275-2286.	1.9	8

#	Article	IF	CITATIONS
73	Artificial Neural Network for Prediction of Venous Thrombosis Recurrence. Blood, 2016, 128, 3771-3771.	0.6	7
74	Current practices of standardized risk assessment for venous thromboembolism: Results from a global survey from the World Thrombosis Day steering committee. Journal of Thrombosis and Haemostasis, 2022, 20, 532-535.	1.9	7
75	Prevalence of transfusion-transmitted Chagas disease among multitransfused patients in Brazil. BMC Infectious Diseases, 2008, 8, 5.	1.3	6
76	Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR. Journal of Thrombosis and Thrombolysis, 2016, 42, 146-153.	1.0	6
77	Epidemiological, clinical, and severity characterization of sickle cell disease in a population from the Brazilian Amazon. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 204-210.	0.6	6
78	Neutrophil activation and circulating neutrophil extracellular traps are increased in venous thromboembolism patients for at least one year after the clinical event. Journal of Thrombosis and Thrombolysis, 2022, 53, 30-42.	1.0	6
79	The Therapeutic Response of Platelet Rich Plasma (PRP) for Androgenetic Alopecia Showed No Correlation with Growth Factors and Platelet Number. Blood, 2016, 128, 2637-2637.	0.6	6
80	Genotype frequencies at codon 129 of the Prion Protein Gene in Brazil: implications in susceptibility to variant Creutzfeldt–Jakob disease compared to European and Asian populations. European Journal of Epidemiology, 2005, 20, 593-595.	2.5	5
81	Early in vivo anticoagulation inhibits the angiogenic response following hindlimb ischemia in a rodent model. Thrombosis and Haemostasis, 2006, 96, 68-72.	1.8	5
82	Performance of a point-of-care device in determining prothrombin time in an anticoagulation clinic. Blood Coagulation and Fibrinolysis, 2012, 23, 172-174.	0.5	5
83	Inflammatory, immune and lipid transportation proteins are differentially expressed in spontaneous and proximal deep vein thrombosis patients. Thrombosis Research, 2012, 130, e246-e250.	0.8	5
84	Clinical implications of the detection of antibodies directed against domain 1 of β2-glycoprotein 1 in thrombotic antiphospholipid syndrome. Thrombosis Research, 2016, 148, 32-37.	0.8	5
85	Role of peripheral blood minimum residual disease at day 8 of induction therapy in high-risk pediatric patients with acute lymphocytic leukemia. Scientific Reports, 2016, 6, 31179.	1.6	5
86	Identification of common and divergent gene expression signatures in patients with venous and arterial thrombosis using data from public repositories. PLoS ONE, 2020, 15, e0235501.	1.1	5
87	Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials. Blood, 2019, 134, 1655-1655.	0.6	5
88	Frequency of Interleukins IL1ß/IL18 and Inflammasome NLRP1/NLRP3 Polymorphisms in Sickle Cell Anemia Patients and their Association with Severity Score. Current Molecular Medicine, 2019, 19, 776-783.	0.6	5
89	Evaluation of the host response to endotoxemia of FVIII and FIX deficient mice. Haemophilia, 2011, 17, 800-807.	1.0	4
90	Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: A case report. Platelets, 2015, 26, 263-266.	1.1	4

#	Article	IF	CITATIONS
91	Residual Vein Thrombosis Echogenicity Is Associated to the Risk of DVT Recurrence: A Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 477-482.	0.7	4
92	Clinical course of primary immune thrombocytopenia with positive antiphospholipid antibodies. European Journal of Internal Medicine, 2019, 69, e6-e7.	1.0	4
93	Endothelial Nitric Oxide Synthase (eNOS) Gene Polymorphisms and Markers of Hemolysis, Inflammation and Endothelial Dysfunction in Brazilian Sickle Cell Anemia Patients. Biochemical Genetics, 2020, 58, 580-594.	0.8	4
94	Deficiency of ARHGAP21 alters megakaryocytic cell lineage responses and enhances platelet hemostatic function. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119012.	1.9	4
95	Metabolic shift of chronic myeloid leukemia patients under imatinib–pioglitazone regimen and discontinuation. Medical Oncology, 2021, 38, 100.	1.2	4
96	Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients. Annals of Hematology, 2021, 100, 2669-2676.	0.8	4
97	Pioglitazone Did Not Affect PPAR-Γ, STAT5, HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response. Blood, 2019, 134, 1637-1637.	0.6	4
98	Autologous Platelet Rich Plasma (PRP) Provoke Immunomodulatory Response By an Increase of Regulatory T Cells (CD4+ CD25+ FOXP3+) with a Decrease of Activated NK Cells (CD16+ CD56+ CD69+) in a Longitudinal Study of Patients with BehħEt's Disease. Blood, 2016, 128, 3849-3849.	0.6	4
99	Circulating Levels of Ang/Tie2 and VEGF-a Pathway Mediators Are Associated with Clinical Severity, Endothelial Barrier Disruption and Coagulation Activation in COVID-19. Blood, 2021, 138, 2073-2073.	0.6	4
100	â€~Leaky gut' in hematological malignancies. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 390-391.	0.7	3
101	Bleeding complications in dengue are not associated with significant changes in the modulators of the endothelial barrier. Journal of Infection in Developing Countries, 2014, 8, 799-803.	0.5	3
102	Severe postthrombotic syndrome is associated with characteristic sonographic pattern of the residual thrombosis. Blood Coagulation and Fibrinolysis, 2016, 27, 673-678.	0.5	3
103	Microvascular thrombosis in sepsis: An autopsy study. Thrombosis Research, 2017, 156, 23-25.	0.8	3
104	Association between histopathological alterations and diarrhea severity in acute intestinal graft-versus-host disease. Medicine (United States), 2018, 97, e0600.	0.4	3
105	B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line. Blood, 2018, 132, 1749-1749.	0.6	3
106	A Meta-Analysis of Gene Expression Studies in Severe Sepsis and Septic Shock. Blood, 2014, 124, 2741-2741.	0.6	3
107	Hydroxychloroquine Therapy and Netosis Regulators Expression in Patients with Primary Antiphospholipid Syndrome. Blood, 2018, 132, 5049-5049.	0.6	3
108	From residency training to professional life: which competencies and skills are most valued by haematologists in Brazil?. Lancet Haematology,the, 2022, 9, e95-e96.	2.2	3

#	Article	IF	CITATIONS
109	Performance of a pointâ€ofâ€care device in determining prothrombin time in supraâ€therapeutic <scp>INR</scp> s. International Journal of Laboratory Hematology, 2013, 35, 211-216.	0.7	2
110	Genetic variations in sites of affinity between FVIII and LRP1 are not associated with high FVIII levels in venous thromboembolism. Scientific Reports, 2015, 5, 9246.	1.6	2
111	Pretransplant β 2 -Microglobulin Is Associated with the Risk of Acute Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2016, 22, 1329-1332.	2.0	2
112	Hypofibrinolysis induced by tranexamic acid does not influence inflammation and mortality in a polymicrobial sepsis model. PLoS ONE, 2019, 14, e0226871.	1.1	2
113	Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors. Blood, 2010, 116, 719-719.	0.6	2
114	Coagulation Activation By Heme: Evidence from Global Hemostasis Assays. Blood, 2014, 124, 455-455.	0.6	2
115	Differential Diagnosis of Hereditary and Acquired Thrombocytopenia By the Immature Platelet Fraction and Thrombopoietin Levels. Blood, 2015, 126, 1049-1049.	0.6	2
116	Increased Levels of Endothelial Dysfunction Markers and Matrix Metalloproteinases in Patients with Severe Post-Thrombotic Syndrome. Blood, 2016, 128, 276-276.	0.6	2
117	Platelet Activation Is Not Crucial for Platelet-Rich Plasma (PRP), When Used As Autologous Therapeutic Product, and Could be Lyophilized without Any Growth Factor Loss. Blood, 2016, 128, 2639-2639.	0.6	2
118	Efeitos do heme livre na fibrinólise: um estudo in vitro e revisão da literatura. , 0, , .		2
119	Association of Plasmic Score with Neurological Symptoms in Patients with Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2019, 134, 4894-4894.	0.6	2
120	Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Blood, 2019, 134, 2938-2938.	0.6	2
121	Evaluation of the mechanisms of heme-induced tissue factor activation: Contribution of innate immune pathways. Experimental Biology and Medicine, 2022, 247, 1542-1547.	1.1	2
122	The role of clotting factor IX in the development of atherosclerosis. Thrombosis Research, 2017, 157, 79-81.	0.8	1
123	Blood Coagulation and Endothelium. , 2018, , 147-152.		1
124	Misdiagnosis of high thrombotic risk triple-positive antiphospholipid antibodies. Thrombosis Research, 2021, 197, 33-35.	0.8	1
125	Changes in heme levels during acute vaso-occlusive crisis in sickle cell anemia. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.6	1
126	On the Links between Arterial and Venous Thrombosis: A Comparative Genomic Analysis of Cardiovascular Disease and Venous Thromboembolism. Blood, 2018, 132, 3807-3807.	0.6	1

#	Article	IF	CITATIONS
127	A Retrospective Analysis of 122 Immune Thrombocytopenia Patients Treated with Dapsone: Efficacy, Safety and Factors Associated with Treatment Response. Blood, 2018, 132, 737-737.	0.6	1
128	ADAMTS13 ACTIVITY and VON Willebrand FACTOR LEVELS IN PATIENTS with Livedoid VASCULOPATHY Blood, 2009, 114, 5064-5064.	0.6	1
129	Hydroxyurea Reduces the Hypercoagulable State In Sickle Cell Anemia. Blood, 2011, 118, 1068-1068.	0.6	1
130	Increased Expression of Secretory Leukocyte Protease Inhibitor (SLPI) In Mononuclear Cells From Patients with Deep Vein Thrombosis. Blood, 2011, 118, 1232-1232.	0.6	1
131	Hydroxyurea Therapy Reduces The Hypercoagulability State In a Sickle Cell Mouse Model. Blood, 2013, 122, 2234-2234.	0.6	1
132	Quelação oral de ferro na Beta-Talassemia. Revista Brasileira De Hematologia E Hemoterapia, 2003, 25, .	0.7	1
133	Decreased Activity of ADAMTS13 In Patients with Deep Vein Thrombosis Associated with Inflammatory Markers. Blood, 2010, 116, 3181-3181.	0.6	1
134	Increased Neutrophil Adhesive Properties In Patients with Venous Thromboembolism and Residual Vein Thrombosis and High D-Dimer Levels. Blood, 2011, 118, 2301-2301.	0.6	1
135	Prothrombin complex concentrates in warfarin anticoagulation reversal. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 302-304.	0.7	1
136	Comments on: frequency of human platelet antigens in oncohematological patients with thrombocytopenia and the probability of incompatibility to platelet transfusions. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 180-181.	0.7	1
137	Plasma Factor VIII Levels as a Biomarker for Venous Thromboembolism. , 2015, , 1-19.		1
138	Sepsis in Patients with Febrile Neutropenia: A Clinical and Autopsy-Based Study. Blood, 2015, 126, 4622-4622.	0.6	1
139	PADI4 Gene Polymorphism As a Risk Factor for Acute Chest Syndrome in Sickle Cell Anemia Patients. Blood, 2017, 130, 954-954.	0.6	1
140	Gene Therapy with Non-Viral Vectors For Critical Limb Ischemia: From Bench to Bedside. , 0, , .		0
141	New developments in the understanding and diagnosis of myelodysplastic syndromes with ring sideroblasts. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 279-280.	0.7	0
142	Bioengineering coagulation factors for improved hemophilia treatments. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 184-185.	0.7	0
143	Tides within ourselves: how posture can affect blood volume, blood cells and clinical reasoning. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 100-101.	0.7	0
144	Clinical course of primary immune thrombocytopenia with positive antiphospholipid antibodies: Author´s reply. European Journal of Internal Medicine, 2020, 74, 108-109.	1.0	0

#	Article	IF	CITATIONS
145	DECREASED ACTIVITY of ADAMTS13 IN PATIENTS with DEEP Vein Thrombosis Blood, 2009, 114, 3991-3991.	0.6	0
146	VKORC1 V66M Mutation in African Brazilian Patient Resistant to Oral Anticoagulant Therapy Blood, 2009, 114, 2102-2102.	0.6	0
147	Analysis of the Genetic Expression of Inflammatory Mediators From Patients with Spontaneous Deep Venous Thrombosis. Blood, 2011, 118, 5251-5251.	0.6	0
148	Six Novel Mutations Identified in the Glycoproteins Ib Alpha, Ib Beta and IX Genes Among Twenty-Two Unrelated Patients with Bernard-Soulier Syndrome in Brazil. Blood, 2011, 118, 1156-1156.	0.6	0
149	Prospective Evaluation of plasma Levels of FVIII in Patients with venous Thromboembolism,. Blood, 2011, 118, 3348-3348.	0.6	0
150	Endothelial Activation, FVW and ADAMTS 13 imbalance and Fibrinolysis Impairment in Adults with Dengue Fever with Bleeding Complications,. Blood, 2011, 118, 3325-3325.	0.6	0
151	Vascular Wall-Related Biomarkers in Sepsis: A Review of Current Evidence and a Critical Appraisal of Recent Patents. Recent Patents on Biomarkers, 2012, 2, 113-118.	0.3	0
152	Thrombotic Thrombocytopenic Purpura Triggered by Inflammatory Pseudotumor: A Report of a Rare Case. Blood, 2012, 120, 4660-4660.	0.6	0
153	Evaluation of Coagulation and inflammatory Markers in Patients with venous Thromboembolism. Blood, 2012, 120, 5131-5131.	0.6	0
154	A High Angiopoietin-2/Angiopoietin-1 Ratio Independently Predicts Septic Shock Development in Patients with Chemotherapy-Associated Febrile Neutropenia and Hematological Malignancies Blood, 2012, 120, 2154-2154.	0.6	0
155	The Utilization of NET Promoter System As a Blood Supply Management Strategy. Blood, 2012, 120, 4378-4378.	0.6	0
156	Metabolic and Inflammatory Proteins Differentially Expressed in Platelets from Unprovoked Deep Vein Thrombosis Patients. Journal of Proteomics and Bioinformatics, 2014, 07, .	0.4	0
157	Lower Echogenicity of the Residual Venous Thrombosis at Ultrasound Examination Is Associated to Recurrent Thrombosis Events. Blood, 2014, 124, 4251-4251.	0.6	0
158	Differentially Expressed Genes and Pathways in Endothelial Cells Exposed to Hemin or Plasma from Patients with Sickle Cell Disease: A Meta-Analysis of Gene Expression Studies. Blood, 2014, 124, 4018-4018.	0.6	0
159	Adhesive Properties of Neutrophils as a Possible Biomarker of Vascular Disease. , 2015, , 1-19.		0
160	Signs of Hypofibrinolysis in Patients with Unprovoked Idiopathic Venous Thromboembolism. Blood, 2015, 126, 3556-3556.	0.6	0
161	A Meta-Analysis of Gene Expression Studies Highlights the Role of Innate Immunity in the Pathogenesis of Sickle Cell Disease and Reveals Novel Potential Regulators at the Transcriptomic Level. Blood, 2015, 126, 4578-4578.	0.6	0
162	Pre-Transplant Beta2-Microglobulin Is an Independent Biomarker of Acute Graft-Versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant in a Single Institutional Study. Blood, 2015, 126, 3152-3152.	0.6	0

#	Article	IF	CITATIONS
163	Increased D-Dimer Levels and Residual Venous Thrombosis Are Associated with Late Recurrence of Deep Venous Thrombosis. Blood, 2015, 126, 3554-3554.	0.6	0
164	Antibodies Directed Against the Domain 1 of Beta2-Glicoprotein 1 May be Associated with Secondary Antiphospholipid Syndrome. Blood, 2015, 126, 768-768.	0.6	0
165	Adhesive Properties of Neutrophils as a Possible Biomarker of Vascular Disease. , 2016, , 985-1003.		0
166	Hypercoagulability and Sickle Cell Disease. , 2016, , 109-127.		0
167	Plasma Factor VIII Levels as a Biomarker for Venous Thromboembolism. , 2016, , 703-721.		0
168	Freeze-Dried Platelet Rich Plasma (PRP) Has Biological Activity in Acute Wound Healing of Animals, Inducing Significantly Angiogenesis. Blood, 2016, 128, 5030-5030.	0.6	0
169	Characteristics of Venous Thrombi in Animal Models of Obesity, Diabetes and Hypertension. Blood, 2016, 128, 5006-5006.	0.6	Ο
170	Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib 400 Mg. Blood, 2016, 128, 1911-1911.	0.6	0
171	Procoagulant Profile in Primary Antiphospholipid Syndrome Is Not Dependent upon Increased Inflammatory Response. Blood, 2016, 128, 3817-3817.	0.6	Ο
172	Increased Inflammatory Properties of Neutrophils in Patients with Venous Thromboembolism and the Effect of Simvastatin on Abrogating Inflamed Neutrophils Adhesiveness. Blood, 2016, 128, 3681-3681.	0.6	0
173	Vinorelbine-Based Hematopoietic Stem-Cell Mobilization: A More Effective, Low-Cost Alternative to Conventional Chemotherapy. Blood, 2018, 132, 4762-4762.	0.6	Ο
174	Clinical Course of Primary Immune Thrombocytopenia with Positive Antiphospholipid Antibodies. Blood, 2018, 132, 1159-1159.	0.6	0
175	Polyphenols Modulate Quiescence/Mobilization of Hematopoietic Immature Cells through APC/EPCR/PAR-1 Axis. Blood, 2018, 132, 3830-3830.	0.6	Ο
176	Exploring Semantics in Clinical Data Interoperability. Lecture Notes in Computer Science, 2019, , 201-210.	1.0	0
177	Quiescence/Mobilization of Hematopoietic Immature Cells Induced By Polyphenols through Modulation of APC/EPCR/PAR-1 Axis. Blood, 2019, 134, 4996-4996.	0.6	Ο
178	COVID-19 Diagnosis and Its Impact on Thrombotic Risk in a Cohort of Patients Simultaneously Hospitalized Due to Acute Respiratory Distress Syndrome. Blood, 2021, 138, 780-780.	0.6	0
179	Reduction of ARHGAP21 Alters Platelet Biogenesis <i>in Vitro</i> and Accelerates Hemostatic Response <i>In Vivo</i> . Blood, 2020, 136, 13-13.	0.6	0
180	Career paths and workforce diversity in hematology: A cross-sectional study of a 35-year alumni cohort from an academic residency program in Brazil. Hematology, Transfusion and Cell Therapy, 2022, , .	0.1	0

#	Article	IF	CITATIONS
181	The landscape of hematology research in Brazil: an analysis of data from citation databases. Hematology, Transfusion and Cell Therapy, 2022, , .	0.1	0
182	Title is missing!. , 2019, 14, e0226871.		0
183	Title is missing!. , 2019, 14, e0226871.		0
184	Title is missing!. , 2019, 14, e0226871.		0
185	Title is missing!. , 2019, 14, e0226871.		0